Report Summarizes DNA Vaccines Study Findings from University of Texas Medical Branch (DNA Vaccine Initiates Replication of Live Attenuated Chikungunya Virus In Vitro and Elicits Protective Immune Response in Mice)
By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Biotechnology. According to news reporting originating in Galveston, Texas, by NewsRx journalists, research stated, "Chikungunya virus (CHIKV) causes outbreaks of chikungunya fever worldwide and represents an emerging pandemic threat. Vaccine development against CHIKV has proved challenging."
The news reporters obtained a quote from the research from the University of Texas Medical Branch, "Currently there is no approved vaccine or specific therapy for the disease. To develop novel experimental CHIKV vaccine, we used novel immunization DNA (iDNA) infectious clone technology, which combines the advantages of DNA and live attenuated vaccines. Here we describe an iDNA vaccine composed of plasmid DNA that encode the full-length infectious genome of live attenuated CHIKV clone 181/25 downstream from a eukaryotic promoter. The iDNA approach was designed to initiate replication of live vaccine virus from the plasmid in vitro and in vivo. Experimental CHIKV iDNA vaccines were prepared and evaluated in cultured cells and in mice. Transfection with 10 ng of iDNA was sufficient to initiate replication of vaccine virus in vitro. Vaccination of BALB/c mice with a single 10 mu g of CHIKV iDNA plasmid resulted in seroconversion, elicitation of neutralizing antibodies, and protection from experimental challenge with a neurovirulent CHIKV. Live attenuated CHIKV 181/25 vaccine can be delivered in vitro and in vivo by using DNA vaccination."
According to the news reporters, the research concluded: "The iDNA approach appears to represent a promising vaccination strategy for CHIK and other alphaviral diseases."
For more information on this research see: DNA Vaccine Initiates Replication of Live Attenuated Chikungunya Virus In Vitro and Elicits Protective Immune Response in Mice. Journal of Infectious Diseases, 2014;209(12):1882-1890. Journal of Infectious Diseases can be contacted at: Oxford Univ Press Inc, Journals Dept, 2001 Evans Rd, Cary, NC 27513, USA. (Oxford University Press - www.oup.com/; Journal of Infectious Diseases - jid.oxfordjournals.org)
Our news correspondents report that additional information may be obtained by contacting I. Tretyakova, Univ Texas Med Branch, Dept. of Pathol, Inst Human Infect & Immun, Galveston, TX 77555, United States. Additional authors for this research include J. Hearn, E. Wang, S. Weaver and P. Pushko (see also Biotechnology).
Keywords for this news article include: Biotechnology, Texas, Genetics, Virology, Galveston, Viral DNA, Alphavirus, RNA Viruses, Togaviridae, Vaccination, DNA Research, DNA Vaccines, Immunization, United States, Medical Devices, Chikungunya Virus, Synthetic Vaccines, Biological Products, Public Health Practice, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC